BR112022021216A2 - Anticorpos, ácido nucleico, célula hospedeira, composições farmacêuticas, métodos de produção de um anticorpo e de tratamento de uma espécie de animal de companhia e métodos para reduzir a função de sinalização de il31 em uma célula e para detectar il31 em uma amostra - Google Patents

Anticorpos, ácido nucleico, célula hospedeira, composições farmacêuticas, métodos de produção de um anticorpo e de tratamento de uma espécie de animal de companhia e métodos para reduzir a função de sinalização de il31 em uma célula e para detectar il31 em uma amostra

Info

Publication number
BR112022021216A2
BR112022021216A2 BR112022021216A BR112022021216A BR112022021216A2 BR 112022021216 A2 BR112022021216 A2 BR 112022021216A2 BR 112022021216 A BR112022021216 A BR 112022021216A BR 112022021216 A BR112022021216 A BR 112022021216A BR 112022021216 A2 BR112022021216 A2 BR 112022021216A2
Authority
BR
Brazil
Prior art keywords
methods
antibodies
cell
antibody
species
Prior art date
Application number
BR112022021216A
Other languages
English (en)
Portuguese (pt)
Inventor
Jiann Li Shyr
Nguyen Lam
Chu Qingyi
Chin Richard
Zhan Hangjun
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of BR112022021216A2 publication Critical patent/BR112022021216A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112022021216A 2020-04-22 2021-04-22 Anticorpos, ácido nucleico, célula hospedeira, composições farmacêuticas, métodos de produção de um anticorpo e de tratamento de uma espécie de animal de companhia e métodos para reduzir a função de sinalização de il31 em uma célula e para detectar il31 em uma amostra BR112022021216A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014033P 2020-04-22 2020-04-22
US202063014549P 2020-04-23 2020-04-23
PCT/US2021/028548 WO2021216810A1 (en) 2020-04-22 2021-04-22 Long-acting anti-il31 antibodies for veterinary use

Publications (1)

Publication Number Publication Date
BR112022021216A2 true BR112022021216A2 (pt) 2022-12-06

Family

ID=78269992

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021216A BR112022021216A2 (pt) 2020-04-22 2021-04-22 Anticorpos, ácido nucleico, célula hospedeira, composições farmacêuticas, métodos de produção de um anticorpo e de tratamento de uma espécie de animal de companhia e métodos para reduzir a função de sinalização de il31 em uma célula e para detectar il31 em uma amostra

Country Status (10)

Country Link
US (1) US20230312702A1 (https=)
EP (1) EP4138914A4 (https=)
JP (1) JP2023524643A (https=)
KR (1) KR20230005875A (https=)
CN (1) CN115666644A (https=)
AU (1) AU2021258198A1 (https=)
BR (1) BR112022021216A2 (https=)
CA (1) CA3173864A1 (https=)
MX (1) MX2022013147A (https=)
WO (1) WO2021216810A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
US20210388053A1 (en) * 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
US20240209096A1 (en) * 2022-12-27 2024-06-27 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
GB202405576D0 (en) * 2024-04-19 2024-06-05 272Bio Ltd VHH antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
US20200181258A1 (en) * 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US12297272B2 (en) * 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
CA3093539A1 (en) * 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
US20210388053A1 (en) * 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
CN113544153B (zh) * 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
US20220169740A1 (en) * 2019-03-20 2022-06-02 Kindred Biosciences, Inc. NGF Antagonists for Medical Use
MX2022011335A (es) * 2020-03-18 2022-10-07 Kindred Biosciences Inc Anticuerpos del receptor anti-interleucina 4 para uso veterinario.

Also Published As

Publication number Publication date
CA3173864A1 (en) 2021-10-28
EP4138914A1 (en) 2023-03-01
WO2021216810A1 (en) 2021-10-28
EP4138914A4 (en) 2024-05-22
US20230312702A1 (en) 2023-10-05
AU2021258198A1 (en) 2022-11-17
CN115666644A (zh) 2023-01-31
MX2022013147A (es) 2023-02-09
KR20230005875A (ko) 2023-01-10
JP2023524643A (ja) 2023-06-13

Similar Documents

Publication Publication Date Title
BR112022021216A2 (pt) Anticorpos, ácido nucleico, célula hospedeira, composições farmacêuticas, métodos de produção de um anticorpo e de tratamento de uma espécie de animal de companhia e métodos para reduzir a função de sinalização de il31 em uma célula e para detectar il31 em uma amostra
BR112022021204A2 (pt) Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra
Ratanapob et al. Prevalence and risk factors for intestinal parasite infection in goats raised in Nakhon Pathom Province, Thailand
CN108330168B (zh) 一种同步检测肉或肉制品中14种动物源性成分的引物组合及其应用
BR112022002771A2 (pt) Anticorpos anti-il31 para uso veterinário
Kamyingkird et al. Prevalence and risk factors associated with Dirofilaria immitis infection in dogs and cats in Songkhla and Satun provinces, Thailand
Arsenopoulos et al. Frequency of resistance to benzimidazoles of Haemonchus contortus helminths from dairy sheep, goats, cattle and buffaloes in Greece
Mateo et al. Prevalence and public health relevance of enteric parasites in domestic dogs and cats in the region of Madrid (Spain) with an emphasis on Giardia duodenalis and Cryptosporidium sp.
Krcmar et al. Identification of species-specific DNA in feedstuffs
BR112022017519A2 (pt) Anticorpos receptores anti-il4 para uso veterinário
Lima-Cordón et al. Implementation science: Epidemiology and feeding profiles of the Chagas vector Triatoma dimidiata prior to Ecohealth intervention for three locations in Central America
Francis et al. Refugia or reservoir? Feral goats and their role in the maintenance and circulation of benzimidazole-resistant gastrointestinal nematodes on shared pastures
Cray et al. Acute phase protein and protein electrophoresis values for captive Grant's zebra (Equus burchelli)
ATE493494T1 (de) Probenherstellungsverfahren mit einem alkali- stoss
Cooke et al. The latest FAD–Faecal antibody detection in cattle. Protocol and results from three UK beef farms naturally infected with gastrointestinal nematodes
El Daous et al. Establishment of a novel diagnostic test for Bovine leukaemia virus infection using direct filter PCR
Patra et al. Single nucleotide polymorphism and expression studies of the interferon gamma gene and its role against Haemonchus contortus in Garole and Sahabadi sheep
Pegels et al. Sensitive detection of porcine DNA in processed animal proteins using a TaqMan real-time PCR assay
Mosikidi et al. Coxiella burnetii (Q Fever) in small ruminants on farms in North West Province, South Africa
Dai et al. May salivary chromogranin A act as a physiological index of stress in transported donkeys? A pilot study
Abo-Aziza et al. Emergent and neglected equine filariosis in Egypt: species diversity and host immune response
Donnik et al. Improving Diagnostic and Eliminating Techniques of Bovine Leukemia in the Russian Federation
Mahlerová et al. Molecular Tools for Lynx spp. qPCR Identification and STR-Based Individual Identification of Eurasian Lynx (Lynx lynx) in Forensic Casework
JP2025514485A5 (https=)
Machado et al. Effect of time and temperature on the detection of PRRSV RNA and endogenous internal sample control in porcine tongue fluids